Clinical analysis of 70 chronic lymphocytic leukemia patients with trisomy 12 detected by FISH
10.3760/cma.j.issn.0253-2727.2018.05.008
- VernacularTitle: FISH检测12号染色体三体阳性慢性淋巴细胞白血病70例临床分析
- Author:
Rui LYU
1
;
Zengjun LI
;
Heng LI
;
Shuhua YI
;
Wei LIU
;
Tingyu WANG
;
Wenjie XIONG
;
Lugui QIU
Author Information
1. Department of Lymphoma, Institute of Hematology & Blood Disease Hospital, State Key Laboratory of Experimental Hematology, CAMS & PUMC, Tianjin 300020, China
- Publication Type:Journal Article
- Keywords:
Leukemia, lymphocytic, chronic;
Trisomy 12;
Clinical characteristic;
Prognosis;
Treatment outcome
- From:
Chinese Journal of Hematology
2018;39(5):387-391
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize and investigate the characteristics, prognosis and treatments of chronic lymphocytic leukemia (CLL) patients with trisomy 12 by using FISH (CEP12).
Methods:Clinical data of 330 CLL patients were analyzed retrospectively by using FISH (CEP12) to detect trisomy 12 from May 2003 to April 2015. The clinical data and laboratory characteristics of CEP12 positive patients (70 cases) were compared with those CEP12 negative patients (260 cases).
Results:Compared with CEP12 negative CLL patients, the proportion of hepatomegaly (13.6% vs 4.0%, P=0.011) and LDH>247 U/L (43.3% vs 18.5%, χ2=15.892, P<0.001) in CEP12 positive CLL patients were much higher, respectively. There were no significant differences between age, sex, clinical stage, β2-microglobulin level, IGHV mutation ratio and splenomegaly/lymphadenopathy in these two subgroups. However, compared with CEP12 negative patients, CEP12 positive patients had higher ratio of FMC7 (23.8% vs 12.7%, χ2=4.730, P=0.030), and lower ratio of CD23 (95.2% vs 99.6%, P=0.033). The overall response rates (ORR) in Fludarabine (without Rituximab), Rituximab (with or without Fludarabine) and the traditional chemotherapy group (chlorambucil, CHOP or CHOP-like) were 77.5% (31/40), 84.8% (56/66) and 45.4% (50/110), respectively. The ORR of the traditional chemotherapy group was lower than that of the Fludarabine group and Rituximab group. For CEP12 positive patients, the ORR was inferior to CEP12 negative patients when only using Fludarabine (P<0.05). However, when using Rituximab, the difference could be eliminated, and the ORR was even a little higher in CEP12 negative patients (91.7% vs 81.0%, P=0.306). Compared with CEP12 negative patients, there were no significant differences in progression-free survival (PFS) (χ2=0.410, P=0.478) and overall survival (OS) (χ2=0.052, P=0.180) for CEP12 positive patients whom the median time from diagnosis to start treatment and OS time was 22.6 (95%CI 15.4-31.7) and 118.5 (95%CI 74.5-162.4) month while the 5-year PFS and OS were (52.9±7.6)% and (74.8±6.6)%.
Conclusions:CEP12 positive CLL patients are more common in hepatomegaly and higher level of LDH. The traditional chemotherapy treatment had the lowest efficacy, and the curative effect of single use of fludarabine is not as good as that of CEP12 negative patients, however, when using Ritaximab, the efficacy could be comparable.
